Flexeril (cyclobenzaprine) is now approved in a 5-mg tablet dose
for use as an adjunct to rest and physical therapy for the relief of
muscle spasm associated with acute, painful, musculoskeletal conditions.
The drug is contraindicated in patients during the acute recovery phase
of myocardial infarction or in patients with arrhythmias, heart block,
conduction disturbances, congestive heart failure, allergies to
cyclobenzaprine or other ingredients in Flexeril, hypothyroidism, or
current or recent use (within 14 days after discontinuation) of
monoamine oxidase inhibitors. For more information, contact McNeil
Consumer & Specialty Pharmaceuticals, 888440-7903,
www.flexeril.info.
Printer friendly
Cite/link
Email
Feedback